强化降压对深部与脑叶脑出血功能结局的影响
该步进式荟萃分析纳入ATACH-2、INTERACT2和INTERACT3三项随机试验,按出血部位分层评估强化降压对功能结局的影响。第一步(ATACH-2+INTERACT2)和第二步(加入INTERACT3)均未发现强化降压在深部或脑叶脑出血中显著改善不良功能结局。
要点
- 强化降压(收缩压目标<140 mmHg)在深部及脑叶脑出血中均未显著改善功能结局。
- 第一步分析深部ICH的OR 0.89(95%CI 0.40-1.98),脑叶ICH的OR 0.92(95%CI 0.73-1.17)。
- 第二步分析深部ICH的OR 0.82(95%CI 0.57-1.18),脑叶ICH的OR 0.97(95%CI 0.76-1.24)。
核心结论
- 强化降压在深部或脑叶脑出血中均未显示显著改善不良功能结局。
- 深部脑出血效应方向及跨试验异质性限制确定性结论。
研究设计与样本
- 步进式荟萃分析,按出血部位分层,纳入ATACH-2、INTERACT2和INTERACT3三项随机试验。
- 第一步合并ATACH-2与INTERACT2(3个月结局,仅强化降压),共2983例深部及537例脑叶脑出血。
- 第二步加入INTERACT3(6个月结局,集束化方案含强化降压、血糖管理、退热及抗凝逆转),共7917例深部及1105例脑叶脑出血。
主要发现
- 第一步:强化降压对深部ICH不良功能结局OR 0.89(95%CI 0.40-1.98;I2=0%),脑叶ICH OR 0.92(95%CI 0.73-1.17;I2=0%)。
- 第二步:深部ICH不良功能结局OR 0.82(95%CI 0.57-1.18;I2=60%),脑叶ICH OR 0.97(95%CI 0.76-1.24;I2=0%)。
关键数值与推荐
- 暴露对比:强化收缩压目标<140 mmHg vs 标准治疗140-180 mmHg。
- 不良功能结局定义:ATACH-2和INTERACT3为改良Rankin量表评分4-6分,INTERACT2为3-6分。
- ATACH-2采用个体患者数据合并结果(校正年龄、GCS评分和脑室内出血),INTERACT2和INTERACT3采用公开合并结果。
临床怎么用
- 现有证据不支持根据出血部位(深部 vs 脑叶)选择强化降压策略以改善功能结局。
- 临床决策仍需结合个体情况,并关注集束化治疗中其他干预措施的综合影响。
局限性
- 各试验结局评估时间点不同(3个月 vs 6个月),且第二步纳入集束化方案,非单纯强化降压。
- 深部ICH分析存在显著异质性(I2=60%),尤其加入INTERACT3后。
- 仅纳入三项试验,统计效力有限,无法排除有临床意义的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Intensive blood pressure (BP) reduction may reduce the risk of poor functional outcomes in patients with acute intracerebral hemorrhage (ICH). Whether these potential benefits apply similarly to lobar and deep ICH, 2 biologically and clinically distinct subtypes, remains uncertain. We tested the hypothesis that intensive BP reduction has differential effects on functional outcomes based on ICH location. METHODS: We performed a stepwise meta-analysis, stratified by ICH location, of 3 landmark randomized clinical trials of intensive BP reduction: Acute Cerebral Hemorrhage (ATACH-2), Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial 2 (INTERACT2), and INTERACT3. Step 1 pooled ATACH-2 and INTERACT2 (3-month outcomes; intensive BP lowering only). Step 2 added INTERACT3 (6-month outcomes; care bundle protocol with intensive BP lowering plus glucose management, antipyresis, and anticoagulant reversal). For ATACH-2, we used pooled results from individual patient data (adjusted for age, Glasgow Coma Scale score, and presence of intraventricular hemorrhage), whereas for INTERACT2 and INTERACT3, we used their pooled, publicly available results. Our exposure of interest contrasted intensive systolic BP targets <140 mm Hg vs standard care 140-180 mm Hg. Our outcome of interest was poor functional outcome, defined as a modified Rankin Scale score of 4-6 in ATACH-2 and INTERACT3 and of 3-6 in INTERACT2. RESULTS: Step 1 included a total of 2,983 patients with deep and 537 patients with lobar ICH (mean age 63 y/o, 37% female). Intensive BP reduction was not associated with a significant difference in poor functional outcome for either deep (odds ratio [OR] 0.89; 95% CI 0.40-1.98; I2 = 0%) or lobar (OR 0.92; 95% CI 0.73-1.17; I2 = 0%) ICH. Step 2 included a total of 7,917 patients with deep and 1,105 patients with lobar ICH (mean age 63 y/o, 37% female). Similarly, intensive BP reduction was not associated with a significant difference in poor outcome in both deep (OR 0.82; 95% CI 0.57-1.18; I2 = 60%) and lobar (OR 0.97; 95% CI 0.76-1.24; I2 = 0%) ICH. DISCUSSION: In this stepwise meta-analysis of 3 landmark ICH trials, intensive BP reduction did not demonstrate a significant benefit in either deep or lobar ICH. Although our estimates did not reach statistical significance, the direction of effect in deep ICH and the substantial heterogeneity across trials, particularly with the inclusion of INTERACT3, limit firm conclusions. Given these uncertainties and the biological distinctions between deep and lobar ICH, future well-powered studies specifically designed to test whether intensive BP reduction has differential effects by hematoma location are warranted.
引用
- Clocchiatti-Tuozzo S, Qureshi AI, Rivier CA, et al. Functional Outcomes After Intensive Blood Pressure Reduction in Deep and Lobar Intracerebral Hemorrhage. Neurology. 2026. PMID: 41962119. doi:10.1212/WNL.0000000000214860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。